A systems biology-based approach to uncovering the molecular mechanisms underlying the effects of dragon's blood tablet in colitis, involving the integration of chemical analysis, ADME prediction, and network pharmacology

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Xu, Haiyu ^a   Zhang, Yanqiong ^a   Lei, Yun ^a,b   Gao, Xiumei ^a,c   Zhai, Huaqiang ^b   Lin, Na ^a   Tang, Shihuan ^a   Liang, Rixin ^a   Ma, Yan ^a   Li, Defeng ^a   Zhang, Yi ^a   Zhu, Guangrong ^d   Yang, Hongjun ^a   Huang, Luqi ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d Yunnan Datang Hanfang Pharmacy Coltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DRAGON BLOOD TABLET; GASTROINTESTINAL AGENT; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CACO 2 CELL LINE; CELL MEMBRANE PERMEABILITY; COLITIS; COMPUTER MODEL; COMPUTER PREDICTION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG SCREENING; DRUG TARGETING; ELECTROSPRAY MASS SPECTROMETRY; HIGH THROUGHPUT SCREENING; METABOLITE; PROCESS OPTIMIZATION; SYSTEMS BIOLOGY; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; CHINESE MEDICINE; HUMAN;

COLITIS; HUMANS; MEDICINE, CHINESE TRADITIONAL; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SYSTEMS BIOLOGY; TANDEM MASS SPECTROMETRY;

EID: 84904913574     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101432     Document Type: Article

References (57)

1. Barnes PM, Powell-Griner E, McFann K, Nahin RL (2004) Complementary and alternative medicine use among adults: United States, 2002. Adv Data 27:1-19.
2. US Food and Drug Administration (2006) Guidance for industry on complementary and alternative medicine products and their regulation by the Food and Drug Administration.
3. Xu H, Tao Y, Lu P, Wang P, Zhang F, et al. (2013) A computational drug-target network for yuanhu zhitong prescription. Evid Based Complement Alternat Med e658531: 1-15.
4. Zhang B, Wang X, Li S (2013) An integrative platform of TCM network pharmacology and its application on a herbal formula, Qing-Luo-Yin. Evid Based Complement Alternat Med e456747: 1-12.
5. Zhang GB, Li QY, Chen QL, Su SB (2013) Network Pharmacology: A New Approach for Chinese Herbal Medicine Research. Evid Based Complement Alternat Med e621423: 1-9.
6. Chen CY (2011) TCM database Taiwan: the world's largest traditional Chinese medicine database for drug screening In Silico. PLoS ONE 6(1): e15939.
7. Li S, Zhang B, Yuan J (2011) A HerbBioMap database. China Copyright of Computer Software. 2011SR076502.
8. Tao Y, Xu H, Wang S, Wang B, Zhang Y, et al. (2013) Identification of the absorbed constituents after oral administration of Yuanhu Zhitong prescription extract and its pharmacokinetic study by rapid resolution liquid chromatography/quadrupole time-of-flight. J Chromatogr B Analyt Technol Biomed Life Sci 935:1-9.
9. Xu H, Li K, Chen Y, Zhang Y, Tang S, et al. (2013) Study on the absorbed fingerprint-efficacy of Yuanhu Zhitong tablet based on chemical analysis, vasorelaxation evaluation and data mining. PLoS One 8(12): e81135.
10. Artursson P, Karlsson J (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficient in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175: 880-885.
11. U.S. Department of Health and Human Services, FDA (2000) Center for Drug Evaluation and Research (CDER) Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. US FDA Guidance for Industry 1-16.
12. Marrero Ponce Y, Cabrera Pérez MA, Romero Zaldivar V, González Díaz H, Torrens F (2004) A new topological descriptors based model for predicting intestinal epithelial transport of drugs in Caco-2 cell culture. J Pharm Pharm Sci 7(2):186-99. (Pubitemid 41528891)
13. State Pharmacopoeia Committee (2010) Pharmacopoeia of the People's republic of china. Beijing: China Medical Science and Technology Press 133.
14. The Editorial Committee (1999) Materia medica of china (volume 8). Shanghai: Shanghai Science and Technology Publishing House 455.
15. Zhu ZY (2012) Nursing experience of longxuejie combined with levofloxacin retention enema in treating ulcerative colitis. J Clin Med Prac 16: 47-49.
16. Hu WB, Gao SH, Gao YL (2011) Treating 40 Cases of Chronic Colitis by Longxuejie plus Western Medicine. J Prac Trad Chin Med 25: 56-57.
17. Feng SH, Liu B, Du R, Sun J (2011) Clinical Observation of Choroidal Neovasularization Treated with Herbal Medicine Longxuejie Tablets. World - J Integra Trad Med 6: 496-498.
18. Arnone A, Nasini G, Merlini L (1990) Constituents of dragon's blood. Part 4. Dracoflavan a, a novel secotri flavanoid. J Chem Soc Perkin 10: 2637-2640.
19. Shen CC, Tsai SY, Wei SL, Wang ST, Shieh BJ, et al. (2007) Flavonoids isolated from draconis resina. Nat Prod Res 21: 377-380.
20. Piozzi F, Passannanti S, Paternostro MP, Nasini G (1974) Diterpenoid resin acids of daemonorops Draco. Phytochemistry 13: 2231-2233.
21. Nasini G, Piozzi F (1981) Pterocarpol and triterpenes from daemonorops. Draco. Phytochemistry 20: 514-516.
22. Shi J, Hu R, Lu Y, Sun C, Wu T (2009) Single-step purification of dracorhodin from dragon's blood resin of Daemonorops draco using high-speed counter-current chromatography combined with pH modulation. J Sep Sci 32: 4040-4047.
23. De Marino S, Gala F, Zollo F, Vitalini S, Fico G, et al. (2008) Identification of minor secondary metabolites from the latex of Croton lechleri (Muell-Arg) and evaluation of their antioxidant activity. Molecules 13:1219-1229.
24. Baumer U, Dietemann P (2010) Identification and differentiation of dragon's blood in works of art using gas chromatography/mass spectrometry. Anal Bioanal Chem 397:1363-76.
25. Yi T, Tang Y, Zhang J, Zhao Z, Yang Z, et al. (2012) Characterization and determination of six flavonoids in the ethnomedicine "Dragon's Blood" by UPLC-PAD-MS. Chem Cent J 6: 116.
26. Milburn M (1984) Dragon's Blood in East & West Africa, Arabia and the Canary Islands. Africa 39: 486-493.
27. Badib AS (1991) Medicinal plants of the Yemen Maktabah Alirsaid: Sanaa 15.
28. Wangensteen H, Klarpås L, Alamgir M, Samuelsen ABC, Malterud KE (2013) Can Scientific Evidence Support Using Bangladeshi Traditional Medicinal Plants in the Treatment of Diarrhoea? A Review on Seven Plants. Nutrients 5: 1757-1800.
29. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36: D901-D906. (Pubitemid 351149842)
30. Chen JY, Mamidipalli SR, Huan TX (2009) HAPPI: an online database of comprehensive human annotated and predicted protein interactions. BMC Genomics (Suppl 1): S16.
31. Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D, et al. (2009) Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res 37: D619-D622.
32. Brown KR, Jurisica I (2005) Online predicted human interaction database. Bioinformatics 21: 2076-2082. (Pubitemid 40668047)
33. Aranda B, Achuthan P, Alam-Faruque Y, Armean I, Bridge A, et al. (2010) The IntAct molecular interaction database in 2010. Nucleic Acids Res 38: D525-D531.
34. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, et al. (2009) Human Protein Reference Database-2009 update. Nucleic Acids Res 37: D767-D772.
35. Ceol A, Chatr Aryamontri A, Licata L, Peluso D, Briganti L, et al. (2010) MINT, the molecular interaction database: 2009 update. Nucleic Acids Res 38: D532-D539.
36. Lehne B, Schlitt T (2009) Protein-protein interaction databases: keeping up with growing interactomes. Hum. Genomics 3: 291-297.
37. Beuming T, Skrabanek L, Niv MY, Mukherjee P, Weinstein H (2005) PDZBase: a protein-protein interaction database for PDZ-domains. Bioinformatics 21: 827-828. (Pubitemid 40439423)
38. Zhang Y, Wang D, Tan S, Xu H, Liu C, et al. (2013) A systems biology-based investigation into the pharmacological mechanisms of Wu Tou Tang acting on rheumatoid arthritis by integrating network analysis. Evid Based Complement Alternat Med e548498: 1-12.
39. Zhu F, Shi Z, Qin C, Tao L, Liu X, et al. (2012) Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 40: D1128-D1136.
40. Wang Y1, Liu Z, Li C, Li D, Ouyang Y, et al (2012) Drug target prediction based on the herbs components: the study on the multitargets pharmacological mechanism of qishenkeli acting on the coronary heart disease. Evid. Based Complement Alternat. Med. 2012: 698531.
41. Azuaje FJ, Zhang L, Devaux Y, Wagner DR (2011) Drug-target network in myocardial infarction reveals multiple side effects of unrelated drugs. Scientific Reports 1: 1-10.
42. Wuchty S, Almaas E (2005) Evolutionary cores of domain co-occurrence networks. BMC Evol Biol 5: 24.
43. Wixon J, Kell D (2000) The Kyoto encyclopedia of genes and genomes - KEGG. Yeast 17: 48-55. (Pubitemid 30406798)
44. Guillarme D, Schappler J, Rudaz S, Veuthey JL (2010) Coupling ultra-highpressure liquid chromatography with mass spectrometry. TrAC Trends Anal Chem 29:15-27.
45. Theodoridis GA, Gika HG, Want EJ, Wilson ID (2012) Liquid chromatographymass spectrometry based global metabolite profiling: a review. Anal Chim Acta 711: 7-16.
46. Michalski A, Damoc E, Hauschild JP, Lange O, Wieghaus A, et al. (2011) Mass spectrometry-based proteomics using Q Exactive, a high-performance benchtop quadrupole Orbitrap mass spectrometer. Mol Cell Proteomics 10: M111.011015.
47. Yovani Marrero P, Miguel Angel C, Vicente Romero Z, Ernest O, Luis AM (2003) Total and local quadratic indices of the "molecular pseudograph's atom adjacency matrix". Application to prediction of Caco-2 permeability of drugs. Int. J Mol Sci 4: 512-536.
48. Zhang J, Zhang Y, Zhang S, Wang S, He L (2010) Discovery of novel taspine derivatives as antiangiogenic agents. Bioorg Med Chem Lett 20: 718-721.
49. Zhou L, Chow MS, Zuo Z (2009) Effect of sodium caprate on the oral absorptions of danshensu and salvianolic acid B. Int J Pharm 379:109-118.
50. Yazdanian M, Glynn SL, Wright JL, Hawi A (1998) Correlating Partitioning and Caco-2 Cell Permeability of Structurally Diverse Small Molecular Weight Compounds. Pharm Res 15: 1490-1494. (Pubitemid 28427942)
51. Li S, Zhang ZQ, Wu LJ, Zhang XG, Li YD, et al. (2007) Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. IET Syst Biol 1: 51-60. (Pubitemid 46779218)
52. Rubino SJ, Selvanantham T, Girardin SE, Philpott DJ (2012) Nod-like receptors in the control of intestinal inflammation. Curr Opin Immunol 24: 398-404.
53. Tomasello G, Sciumé C, Rappa F, Rodolico V, Zerilli M, et al. (2011) Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapy. Eur J Histochem 55: e38.
54. Wine E, Mack DR, Hyams J, Otley AR, Markowitz J, et al. (2013) Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. J Crohns Colitis 7: 916-922.
55. Lv R, Qiao W, Wu Z, Wang Y, Dai S, et al. (2014) Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One 9: e86692.
56. Horwitz B (2005) NF-kappa B, an inhibitor of microflora-induced colitis. J Pediatr Gastroenterol Nutr 40 (Suppl 1): S22-3.
57. Sikander A, Rana SV, Sharma SK, Sinha SK, Arora SK, et al. (2010) Association of alpha 2A adrenergic receptor gene (ADRAlpha2A) polymorphism with irritable bowel syndrome, microscopic and ulcerative colitis. Clin Chim Acta 411: 59-63.